Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasm Metastasis 2Multiple Myeloma 2Stomach Neoplasms 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Keratoacanthoma familial 1Hodgkin Disease 1Hematologic Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Camurati-Engelmann Syndrome 1

Interventions

Cisplatin 2vactosertib 1fludarabine 1enzalutamide 1bintrafusp alfa protein, human 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Paclitaxel 1LY3300054 1Gemcitabine 1Fenretinide 1Cyclophosphamide 1Carboplatin 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Camurati-Engelmann Syndrome × vactosertib × Clear all
NCT02160106 2019-05-09

First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors

MedPacto, Inc.

Phase 1 Completed
35 enrolled

Keratoacanthoma familial, Camurati-Engelmann Syndrome, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡